NASDAQ:GHDX - Genomic Health Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$63.44
+0.30 (1.20%)
Get New Genomic Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GHDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GHDX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Genomic Health in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $63.44.

This chart shows the closing price for GHDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Genomic Health. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/30/2019Needham & Company LLCDowngradeStrong-Buy ➝ HoldLow
7/30/2019BarclaysUpgradeUnderweight ➝ Equal Weight$45.00 ➝ $72.00Low
7/29/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$60.00 ➝ $72.00High
7/29/2019Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralHigh
6/20/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$72.00Low
6/19/2019Needham & Company LLCSet Price TargetBuy$69.00Medium
5/30/2019Deutsche Bank AktiengesellschaftLower Price TargetHold$80.00 ➝ $55.00Low
5/9/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$97.00 ➝ $69.00Medium
2/21/2019Piper Jaffray CompaniesBoost Price TargetNeutral$86.00High
2/21/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$86.00 ➝ $97.00High
1/2/2019Needham & Company LLCInitiated CoverageStrong-Buy ➝ Strong-Buy$86.00Low
12/19/2018CIBCInitiated CoverageMarket Perform ➝ Market PerformMedium
12/19/2018OppenheimerInitiated CoverageMarket PerformHigh
10/23/2018Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformLow
8/6/2018CowenReiterated RatingHold$50.00Low
8/3/2018Piper Jaffray CompaniesReiterated RatingHold$60.00High
8/3/2018Jefferies Financial GroupReiterated RatingHold$50.00High
7/27/2018Piper Jaffray CompaniesBoost Price TargetNeutral ➝ Neutral$34.00 ➝ $50.00Medium
6/13/2018LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$33.00Low
5/3/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$32.00 ➝ $34.00Medium
3/8/2018Piper Jaffray CompaniesReiterated RatingHold$33.00High
1/8/2018BarclaysReiterated RatingSell$28.00Medium
12/20/2017William BlairDowngradeOutperform ➝ Market PerformLow
12/13/2017JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$25.00High
10/20/2017Jefferies Financial GroupReiterated RatingHold$34.00N/A
9/14/2017Jefferies Financial GroupReiterated RatingHold$33.00Low
9/1/2017CowenReiterated RatingHold$34.00Low
8/3/2017Piper Jaffray CompaniesReiterated RatingHold$31.00Low
(Data available from 7/1/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/3/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/1/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Genomic Health logo
Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.
Read More

Today's Range

Now: $63.44
Low: $63.44
High: $63.44

50 Day Range

MA: $64.79
Low: $63.44
High: $69.79

52 Week Range

Now: $63.44
Low: $50.77
High: $90.18

Volume

N/A

Average Volume

1,049,573 shs

Market Capitalization

$2.38 billion

P/E Ratio

60.42

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Genomic Health?

The following Wall Street sell-side analysts have issued stock ratings on Genomic Health in the last year:
View the latest analyst ratings for GHDX.

What is the current price target for Genomic Health?

0 Wall Street analysts have set twelve-month price targets for Genomic Health in the last year.
View the latest price targets for GHDX.

What is the current consensus analyst rating for Genomic Health?

Genomic Health currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GHDX.

How do I contact Genomic Health's investor relations team?

Genomic Health's physical mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company's listed phone number is 650-556-9300 and its investor relations email address is [email protected] The official website for Genomic Health is www.genomichealth.com. Learn More about contacing Genomic Health investor relations.